Comparable stake leader
Thomas A. Satterfield Jr.
SEC ownership of Lantern Pharma Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001763950.
Disclosed value leader
Aaron G.l. Fletcher
Comparable rows
37/45
Latest evidence
15 May 2026
- Public ticker
- LTRN on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Thomas A. Satterfield Jr.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
37 of 45
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Thomas A. Satterfield Jr.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
15 May 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001763950
- Issuer location
- Dallas, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Lantern Pharma Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Thomas A. Satterfield Jr.
Disclosed value leader
Aaron G.l. Fletcher
Comparable rows
37/45
Latest evidence
15 May 2026
13D/G
3/4/5
13F
Lead comparable stake: 5.1%
8 rows are not safely comparable across share classes.
13D/G row: Thomas A. Satterfield Jr.
Showing 1-8 of 45 holder rows.
Quick read
Thomas A. Satterfield Jr. leads the comparable SEC ownership view at 5.1%.
37 of 45 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Thomas A. Satterfield Jr.'s linked filing trail.
Comparable ownership
Top 5
Thomas A. Satterfield Jr.
5.1%
Bios Equity Partners, LP
4.5%
Aaron G.l. Fletcher
8.4%
Leslie W. Kreis
8.4%
BIOS Capital Management, LP
6.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 45 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Thomas A. Satterfield Jr. |
13D/G
|
5.1%
|
$1,727,100
570,000 shares
|
$0 | 30 Mar 2026 |
| Bios Equity Partners, LP |
13D/G
BIOS ADVISORS GP, LLC
|
4.5%
|
$1,125,471
571,305 shares
|
-$518,991 | 15 May 2026 |
| Aaron G.l. Fletcher |
3/4/5
10%+ Owner
|
8.4%
|
$3,344,781
1,075,952 shares
|
— | 13 Jun 2025 |
| Leslie W. Kreis |
3/4/5
10%+ Owner
|
8.4%
|
$3,344,781
1,075,952 shares
|
— | 13 Jun 2025 |
| BIOS Capital Management, LP |
13F
Company
|
6.8%
|
$1,184,276
864,435 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
2.6%
|
$454,948
332,079 shares
|
— | 31 Mar 2026 |
| CM Management, LLC |
13F
Company
|
2%
|
$342,500
250,000 shares
|
— | 31 Mar 2026 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
0.91%
|
$158,920
116,000 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$200,001.
Buys
$200,001
Insiders: 2
Sells
$0
Insiders: 0
Net
+$200,001
Shares: +97,088
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 97,088
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 97,088 | 0 | $200,001 | $0 | +$200,001 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to Lantern Pharma Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
Aaron G.l. Fletcher
Net 12M change
+$200,002
Latest report
12 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Aaron G.l. Fletcher | 10%+ Owner | $3,344,781 | Mixed | 13 Jun 2025 | ||
| Leslie W. Kreis | 10%+ Owner | $3,344,781 | Mixed | 13 Jun 2025 | ||
| Donald Jeffrey Keyser | Director | $194,264 | +$100,001 | +106% | Filing P/S | 12 May 2026 |
| Lee T. Schalop | Director | $100,000 | +$100,001 | +100% | Filing P/S | 12 May 2026 |
| Vijay Chandru | Director | Mixed | 09 Jan 2026 | |||
| David R. Margrave | Chief Financial Officer | Mixed | 18 Dec 2025 | |||
| Franklyn G. Prendergast | Director | Mixed | 04 Nov 2021 | |||
| Kishor G. Bhatia | Chief Scientific Officer | Mixed | 18 Dec 2025 | |||
| Maria-Luisa Maccecchini | Director | Mixed | 09 Jan 2026 | |||
| David S. Silberstein | Director | Mixed | 09 Jan 2026 | |||
| Panna Sharma | President & CEO, Director | Mixed | 19 Sep 2025 |
Recent insider transactions for Lantern Pharma Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Lee T. Schalop | LTRN | Common stock, $0.001 par value | Purchase | $100,001 | $2.06 | 48,544 | 48,544 | 12 May 2026 | Direct | |
| Lee T. Schalop | LTRN | Common stock purchase warrant (Right to Buy) | Purchase | -50% | -48,544 | 48,544 | 12 May 2026 | Direct | ||
| Donald Jeffrey Keyser | LTRN | Common stock, $0.001 par value | Purchase | 106.1% | $100,001 | $2.06 | 48,544 | 94,303 | 12 May 2026 | Direct |
| Donald Jeffrey Keyser | LTRN | Common stock purchase warrant (Right to Buy) | Purchase | -50% | -48,544 | 48,544 | 12 May 2026 | Direct | ||
| D. Jeffrey Keyser | LTRN | Stock Option (Right to Buy) | Award | 53,844 | 28,844 | 09 Jan 2026 | Direct | |||
| Maria-Luisa Maccecchini | LTRN | Stock Option (Right to Buy) | Award | 46,152 | 25,000 | 09 Jan 2026 | Direct | |||
| Vijay Chandru | LTRN | Stock Option (Right to Buy) | Award | 42,307 | 25,000 | 09 Jan 2026 | Direct | |||
| Lee T. Schalop | LTRN | Stock Option (Right to Buy) | Award | 43,460 | 25,000 | 09 Jan 2026 | Direct | |||
| David S. Silberstein | LTRN | Stock Option (Right to Buy) | Award | 42,307 | 25,000 | 09 Jan 2026 | Direct | |||
| David R. Margrave | LTRN | Stock Option (Right to Buy) | Award | 20,000 | 20,000 | 18 Dec 2025 | Direct | |||
| Kishor G. Bhatia | LTRN | Stock Option (Right to Buy) | Award | 10,000 | 10,000 | 18 Dec 2025 | Direct | |||
| Lee T. Schalop | LTRN | Stock Option (Right to Buy) | Award | 5,000 | 5,000 | 19 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.